Program
rocbrutinib
Also written as “Rocbrutinib”, “LP-168 tablet” and “LP-168”.
Its studies are mostly in Lymphoma, Mantle-Cell · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Sclerosis, Relapsing-Remitting · Waldenstrom Macroglobulinemia, led by 2 companies.
Drug pageRocbrutinib: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lupeng Pharmaceuticalits history only | 1411 open or running | phase 3since Jan 13, 2026 | Feb 22, 2021 | Mar 31, 2027phase 1 · NCT04993690 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 2since Mar 4, 2025 | Mar 4, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named rocbrutinibINNProposed as its International Nonproprietary Name in WHO's List 129 · before, LP-168
- Mar 4, 2025First study: phase 2 study in Chronic UrticariaFirst studyNCT06864507 · 150 planned · China
TargetBeta
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The one study Hansoh Pharmaceutical Group leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06864507Chronic Urticaria · China | 2 | Not yet recruiting | Sep 27, 2026 | 150 |
How it is read
Names in the registry
- “Rocbrutinib”, 7 entries
- “LP-168 tablet”, 3 entries
- “LP-168”, 2 entries
- “Lacutoclax+Rocbrutinib”, 1 entry
- “Rocbrutinib tablets”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Mantle-Cell, 4 studies
- Lymphoma, B-Cell, 2 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 study
- Multiple Sclerosis, Relapsing-Remitting, 1 study
- Waldenstrom Macroglobulinemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.